{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:37:08Z","timestamp":1753893428023,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Waldenstr\u00f6m macroglobulinemia (WM) is a rare subtype of B-cell lymphoma. Rituximab-based combination therapy and Bruton\u2019s tyrosine kinase (<jats:italic>BTK<\/jats:italic>) inhibitors have greatly improved the prognosis of WM. Despite the high response rate and good tolerance of <jats:italic>BTK<\/jats:italic> inhibitors in treatment of WM, a proportion of patients still experience disease progression.<\/jats:p><jats:p><jats:bold>Case presentation:<\/jats:bold> We report a 55-year-old man with relapsed WM. The patient achieved partial remission after six courses of CHOP chemotherapy and multiple plasma exchanges in initial treatment. He was admitted to the hospital with abdominal distension, and was diagnosed with relapsed WM and subsequently started on zanubrutinib. Disease progression and histological transformation occurred during treatment. We performed liquid biopsies on transformed plasma, tumor tissue and ascites at the same time and found high consistency between ascites and tissues. Moreover, we detected resistance mutations of <jats:italic>BTK<\/jats:italic> inhibitors (<jats:italic>BTK<\/jats:italic>, <jats:italic>PLCG2<\/jats:italic>) in ascites that were not detected in plasma or tissue. Eventually, the patient died during the 15-month follow-up after relapse.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We describe a rare case of WM transformation to DLCBCL treated with chemoimmunotherapy and <jats:italic>BTK<\/jats:italic> inhibition. We analyzed tumor DNA obtained at different anatomic sites and circulating tumor DNA (ctDNA) derived from plasma and ascites specimens, with apparent significant temporal and spatial heterogeneity. The case specifically highlights the clinical value of ctDNA of ascites supernatant from WM patients, which is a more convenient and relatively noninvasive method compared with traditional invasive tissue biopsy.<\/jats:p>","DOI":"10.3389\/pore.2023.1611070","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:11:32Z","timestamp":1681877492000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenstr\u00f6m macroglobulinemia during treatment with BTK inhibitors"],"prefix":"10.3389","volume":"29","author":[{"given":"Jingjing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huina","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international Workshop on waldenstrom's macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ajh.26082","article-title":"Waldenstr\u00f6m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management","volume":"96","author":"Gertz","year":"2021","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/s2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth international Workshop for Waldenstr\u00f6m macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1038\/s41375-018-0197-7","article-title":"Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies","volume":"32","author":"Bagratuni","year":"2018","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"12932","DOI":"10.3390\/ijms232112932","article-title":"Read count patterns and detection of cancerous copy number alterations in plasma cell-free DNA whole exome sequencing data for advanced non-small cell lung cancer","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12916-022-02595-8","article-title":"Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: A prospective cohort study (GASTO 1028)","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/1535-7163.Mct-16-0436","article-title":"Cell-Free DNA from ascites and pleural effusions: Molecular insights into genomic aberrations and disease biology","volume":"16","author":"Husain","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2009-05-174359","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"114","author":"Treon","year":"2009","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/jco.19.02314","article-title":"Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11864-016-0425-1","article-title":"Circulating tumor DNA to monitor therapy for aggressive B-cell lymphomas","volume":"17","author":"Kwok","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1182\/blood-2018-10-880690","article-title":"Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS","volume":"133","author":"Nakamura","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"14756","DOI":"10.1038\/ncomms14756","article-title":"Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.3390\/cancers14174136","article-title":"Circulating tumour cells, cell free DNA and tumour-educated platelets as reliable prognostic and management biomarkers for the liquid biopsy in multiple myeloma","volume":"14","author":"Allegra","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"E148","DOI":"10.1002\/ajh.25802","article-title":"Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations","volume":"95","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1182\/bloodadvances.2021005354","article-title":"Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies","volume":"6","author":"Bagratuni","year":"2022","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/cup.12944","article-title":"MYD88 L265P mutation in cutaneous involvement by Waldenstr\u00f6m macroglobulinemia","volume":"44","author":"Alegr\u00eda-Landa","year":"2017","journal-title":"J Cutan Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.14386","article-title":"MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr\u00f6m macroglobulinaemia","volume":"180","author":"Gustine","year":"2018","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hon.2489","article-title":"The use of droplet digital pcr in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid","volume":"36","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Hematological Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1186\/s12885-022-09922-5","article-title":"Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers","volume":"22","author":"Wu","year":"2022","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/15384047.2018.1504720","article-title":"Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient","volume":"20","author":"Zhou","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.hoc.2018.05.012","article-title":"First-Generation and second-generation Bruton tyrosine kinase inhibitors in Waldenstr\u00f6m macroglobulinemia","volume":"32","author":"Argyropoulos","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTK(Cys481Ser) drives ibrutinib resistance via ERK1\/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/bjh.17502","article-title":"Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukaemia during ibrutinib therapy","volume":"194","author":"B\u00f6d\u00f6r","year":"2021","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjh.15610","article-title":"Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenstr\u00f6m Macroglobulinaemia reveals different patterns of clonal evolution","volume":"185","author":"Talaulikar","year":"2019","journal-title":"Br J Haematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1158\/1078-0432.Ccr-17-0007","article-title":"TP53 mutation and its prognostic significance in waldenstrom's macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13543784.2017.1275561","article-title":"Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia","volume":"26","author":"Gavriatopoulou","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"B36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1309\/r01v-xg46-mfcd-vnhl","article-title":"Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia. Clinicopathologic features of 12 cases","volume":"120","author":"Lin","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/ajh.24477","article-title":"Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr\u00f6m macroglobulinemia","volume":"91","author":"Castillo","year":"2016","journal-title":"Am J Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bjh.14881","article-title":"Transformed Waldenstr\u00f6m macroglobulinaemia: Clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French innovative leukemia organization (FILO)","volume":"179","author":"Durot","year":"2017","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1038\/bcj.2017.72","article-title":"From Waldenstr\u00f6m's macroglobulinemia to aggressive diffuse large B-cell lymphoma: A whole-exome analysis of abnormalities leading to transformation","volume":"7","author":"Jim\u00e9nez","year":"2017","journal-title":"Blood Cancer J"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:11:36Z","timestamp":1681877496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1611070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":39,"alternative-id":["10.3389\/pore.2023.1611070"],"URL":"https:\/\/doi.org\/10.3389\/pore.2023.1611070","relation":{},"ISSN":["1532-2807"],"issn-type":[{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"article-number":"1611070"}}